Director Jennifer E. Cook sold 39.4K shares of BBIO for $2.8M via 2 separate sales (June 23–24, 2026), 82.4% of pre-transaction holdings, under 10b5-1 plan.
Jennifer E. Cook, a director at BridgeBio Pharma, executed 2 separate sales totaling 39,363 shares for $2,752,269.72 on June 23–24, 2026, at an average of $69.92 per share. The sales reduced her non-derivative holdings from 47,746 shares to 8,383 shares, representing an 82.4% reduction in that portion of her position. However, the FLAG indicates this activity was scheduled under a 10b5-1 trading plan adopted on 2026-03-16, meaning the sales were pre-arranged and not discretionary timing decisions by the director. The insider retains 41,444 shares in derivative form (stock options), so her economic interest in the company remains substantial. At a company with $13.6B market cap and most recent quarterly revenue of $194.5M but a full-year net income of $-166.6M, scheduled open-market sales of this magnitude warrant monitoring, particularly alongside her prior sales on 2026-06-15. The current stock price of $69.36 sits 18.3% below the 52-week high of $84.94, providing context for the execution price but not explaining the underlying schedule.